Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	34.12	42.91	71.34	88.4	53.64	96.45
Short-Term Investments	204.43	178.08	156.62	183.46	355.95	290.61
Cash & Short-Term Investments	238.55	220.98	227.96	271.86	409.59	387.06
Cash Growth	25.01%	-3.06%	-16.15%	-33.63%	5.82%	36.08%
Accounts Receivable	155.16	146.23	73.07	25.81	8.46	-
Receivables	155.16	146.23	73.07	25.81	8.46	-
Inventory	38.88	22.63	14.53	13.13	7.51	-
Prepaid Expenses	18	11.59	12.29	10.1	7.39	14.17
Restricted Cash	0.31	0.31	0.62	0.93	1.23	1.54
Other Current Assets	16.77	9.49	7.37	8.61	3.23	-
Total Current Assets	467.67	411.23	335.82	330.43	437.41	402.77
Property, Plant & Equipment	5.13	5.51	2.99	3.9	4.6	5.3
Other Intangible Assets	13.69	14.81	9.48	6.44	7.19	-
Other Long-Term Assets	2.05	1.42	0.6	0.6	0.08	0.08
Total Assets	488.54	432.97	348.89	341.37	449.27	408.15

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	6.6	12.53	14.22	11.99	8.83	7.35
Accrued Expenses	146.79	116.02	66.79	33.94	28.32	25.54
Current Portion of Long-Term Debt	6.95	1	-	-	-	-
Current Portion of Leases	-	0.29	-	0.74	0.66	0.43
Total Current Liabilities	160.34	129.84	81.01	46.67	37.81	33.33
Long-Term Debt	101.95	107.96	107.2	201.8	197.77	72.35
Long-Term Leases	5.24	5.27	2.56	3.38	4.12	4.77
Other Long-Term Liabilities	0.43	0.43	0.57	0.85	-	0.03
Total Liabilities	267.96	243.49	191.35	252.7	239.69	110.48

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,356	1,328	1,279	1,071	930.43	706.23
Retained Earnings	-1,134	-1,138	-1,122	-981.9	-719.76	-408.31
Comprehensive Income & Other	-0.66	-0.04	-0.01	0	-1.09	-0.26
Total Common Equity	220.58	189.48	157.54	88.67	209.58	297.68
Shareholders' Equity	220.58	189.48	157.54	88.67	209.58	297.68
Total Liabilities & Equity	488.54	432.97	348.89	341.37	449.27	408.15

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	114.14	114.52	109.77	205.92	202.54	77.56
Net Cash (Debt)	124.42	106.46	118.19	65.95	207.05	309.5
Net Cash Growth	54.25%	-9.92%	79.22%	-68.15%	-33.10%	10.74%
Net Cash Per Share	0.94	0.84	0.98	0.95	3.76	6.26
Filing Date Shares Outstanding	125.69	124.03	118.64	96.81	61.08	50.38
Total Common Shares Outstanding	125.59	123.33	117.85	96.79	61.04	50.26
Working Capital	307.33	281.39	254.81	283.76	399.6	369.45
Book Value Per Share	1.76	1.54	1.34	0.92	3.43	5.92
Tangible Book Value	206.89	174.67	148.06	82.23	202.39	297.68
Tangible Book Value Per Share	1.65	1.42	1.26	0.85	3.32	5.92
Machinery	-	2.62	1.93	1.79	1.36	1.12
Leasehold Improvements	-	1.57	1.57	1.57	1.57	1.57

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 14, 2026

Data Sources Report a data error